期刊
JOURNAL OF CONTROLLED RELEASE
卷 119, 期 2, 页码 197-206出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2007.02.004
关键词
bioavailability; cyclosporine; narroparticles; nephrotoxicity; oral delivery; pharmacokinetics
The cyclosporine-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs) were prepared by the emulsion-diffusion-evaporation method and were optimized for particle size and entrapment efficiency. The optimized particles were 143.3 +/- 8.7 nm in size with narrow size distribution and 71.9 +/- 1.7% entrapment efficiency at 20% w/w initial drug loading when prepared with 0.1% w/v of Didodecylmetbylammonium bromide (DMAB) as stabilizer. These particulate carriers exhibited controlled in vitro release of cyclosporine for 23 days at a nearly constant rate and showed very good hemocompatibility in vitro. The nanoparticulate formulation showed significantly higher intestinal uptake as compared to Sandimmune Neoral (R) and cyclosporine suspension. The relative bioavailability of nanoparticulate formulation was found to be 119.2% as compared to Sandimmune Neoral (R). A marked difference in the pharmacokinetic profile between nanoparticulate and Sandimmune Neoral (R) formulations was observed where nanoparticulate formulation showed controlled release of cyclosporine over 5 days, on the other hand, the marketed formulation showed a sharp C-max with a 3-day release profile. The nanoparticulate formulation exerted significantly lower nephrotoxicity in the rats as compared to Sandimmune Neoral (R), which was evidenced by lower blood urea nitrogen (BUN), plasma creatinine (PC) and malondialdehyde (MDA) levels in plasma and kidney. The results were further supported by the histopathological changes in kidneys. Together, these results indicate that PLGA NPs have greater potential for oral delivery of cyclosporine. (C) 2007 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据